Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
22.51 CNY -1.14% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. -1.87% -10.07%
Apr. 18 China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy MT
Apr. 17 Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator MT

Business Summary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:

- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;

- sale of medical equipments and diagnosis products (17.3%);

- medical and hospital services (10.5%);

- other (0.1%).

China accounts for 72.9% of net sales.

Number of employees: 40,370

Sales per Business

CNY in Million2022Weight2023Weight Delta
Pharmaceutical
73.0 %
30,812 70.1 % 30,222 73.0 % -1.91%
Medical and Health Services
16.1 %
6,080 13.8 % 6,672 16.1 % +9.74%
Medical Devices and Medical Diagnosis
10.6 %
6,949 15.8 % 4,390 10.6 % -36.83%
Other
0.3 %
110 0.3 % 115 0.3 % +4.48%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
74.9 %
30,013 68.3 % 31,029 74.9 % +3.38%
Other Countries or Regions
25.1 %
13,938 31.7 % 10,371 25.1 % -25.60%

Managers

Managers TitleAgeSince
De Yong Wen CEO
 Chief Executive Officer 52 -
Dong Ming Li PSD
 President 55 20-10-28
Yi Fang Wu CHM
 Chairman 54 04-03-31
Ke Xin Wang CHM
 Chairman 60 20-10-28
Shirley Wu DFI
 Director of Finance/CFO 44 16-12-31
Hequn Yin CTO
 Chief Tech/Sci/R&D Officer 60 -
Qi Yu Chen BRD
 Director/Board Member 52 94-03-31
Fang Yao BRD
 Director/Board Member 54 10-04-08
Rong Li Feng PRN
 Corporate Officer/Principal 49 -
Ai Min Hui SAM
 Sales & Marketing 61 -

Members of the board

Members of the board TitleAgeSince
Fang Yao BRD
 Director/Board Member 54 10-04-08
Qi Yu Chen BRD
 Director/Board Member 52 94-03-31
Xiao Hui Guan BRD
 Director/Board Member 53 -
Yi Fang Wu CHM
 Chairman 54 04-03-31
Xiao Liang Xu BRD
 Director/Board Member 51 19-06-24
Ke Xin Wang CHM
 Chairman 60 20-10-28
Dong Hui Pan BRD
 Director/Board Member 54 20-06-29
De Yong Wen CEO
 Chief Executive Officer 52 -
Qian Ren CHM
 Chairman 55 18-01-10
Quan Di Wang BRD
 Director/Board Member 74 21-06-10

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 551,940,500 473,969,000 ( 85.87 %) 0 63.42 %
Stock B 1 2,122,427,597 1,222,025,582 ( 57.58 %) 1,969,386 ( 0.0928 %)

Shareholders

NameEquities%Valuation
FOSUN INTERNATIONAL LIMITED
12.96 %
71,533,500 12.96 % 117 M ¥
BlackRock Fund Advisors
1.566 %
8,643,000 1.566 % 14 M ¥
BlackRock Advisors (UK) Ltd.
1.346 %
7,430,500 1.346 % 12 M ¥
Bosera Asset Management Co., Ltd.
0.7017 %
3,873,000 0.7017 % 6 M ¥
Atalanta Sosnoff Capital LLC
0.4695 %
2,591,500 0.4695 % 4 M ¥
BlackRock (Netherlands) BV
0.3235 %
1,785,761 0.3235 % 3 M ¥
China Asset Management Co., Ltd.
0.3081 %
1,700,500 0.3081 % 3 M ¥
State Street Global Advisors Ltd.
0.2192 %
1,209,797 0.2192 % 2 M ¥
BlackRock Investment Management (UK) Ltd.
0.2038 %
1,124,704 0.2038 % 2 M ¥
Sjunde AP-fonden
0.1738 %
959,500 0.1738 % 2 M ¥
NameEquities%Valuation
Yi Fang Wu
13.06 %
257,200 13.06 % 820 982 ¥
Ke Xin Wang
10.93 %
215,200 10.93 % 686 918 ¥
Xiao Hui Guan
9.500 %
187,100 9.500 % 597 223 ¥
De Yong Wen
9.500 %
187,100 9.500 % 597 223 ¥
Rong Li Feng
4.748 %
93,500 4.748 % 298 452 ¥
Dong Hua Wang
4.748 %
93,500 4.748 % 298 452 ¥
Jing Li
4.748 %
93,500 4.748 % 298 452 ¥
Qin Gui Bao
2.376 %
46,800 2.376 % 149 386 ¥
Yi Liu
2.376 %
46,800 2.376 % 149 386 ¥
Yue Zhu
2.376 %
46,800 2.376 % 149 386 ¥
NameEquities%Valuation
FOSUN INTERNATIONAL LIMITED
41.85 %
886,315,955 41.85 % 2 829 M ¥
Perseverance Asset Management LP
2.249 %
47,619,047 2.249 % 152 M ¥
China Securities Finance Corp. Ltd.
1.829 %
38,736,079 1.829 % 124 M ¥
China Merchants Fund Management Co., Ltd.
1.263 %
26,751,887 1.263 % 85 M ¥
UBS Asset Management Switzerland AG
0.9489 %
20,095,238 0.9489 % 64 M ¥
CHINA CONSTRUCTION BANK CORPORATION
0.8953 %
18,960,946 0.8953 % 61 M ¥
China Asset Management Co., Ltd.
0.6986 %
14,794,673 0.6986 % 47 M ¥
Yinhua Fund Management Co., Ltd.
0.4748 %
10,055,629 0.4748 % 32 M ¥
Yunnan Qijia Investment Co. , Ltd.
0.3729 %
7,896,749 0.3729 % 25 M ¥
Tian Hong Asset Management Co., Ltd.
0.3710 %
7,856,089 0.3710 % 25 M ¥

Holdings

NameEquities%Valuation
GLAND PHARMA LIMITED
57.86%
 95,293,894 57.86% 2,104,515,143 $
SISRAM MEDICAL LTD
71.42%
 334,504,800 71.42% 150,871,700 $
SHANGHAI HENLIUS BIOTECH, INC.
21.74%
 35,523,439 21.74% 61,819,665 $
YSB INC.
7.61%
 48,721,760 7.61% 50,549,313 $
C.Q. PHARMACEUTICAL HOLDING CO., LTD.
0.99%
 17,186,726 0.99% 12,389,223 $

Company contact information

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Building A No. 1289 Yishan Road

200233, Shanghai

+86 21 3398 7000

http://www.fosunpharma.com
address Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(600196)

Group companies

NameCategory and Sector
Chindex Hong Kong Ltd.

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
22.51 CNY
Average target price
29.75 CNY
Spread / Average Target
+32.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Stock Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-10.07% 7.48B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.